Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor

Producción científica: Review articlerevisión exhaustiva

117 Citas (Scopus)


The SGLT2 inhibitors (SGLTi) and glucagon-like-1 receptor agonists (GLP-1 RAs) effectively reduce HbA1c, but via very different mechanisms, making them an effective duet for combination therapy. Recently, drugs in both of these antidiabetic classes have been shown to reduce cardiovascular events, most probably by different mechanisms. SGLT2i appear to exert their CV protective actions by haemodynamic effects, while GLP-1 RAs work via anti-atherogenic/anti-inflammatory mechanisms, raising the possibility that combined therapy with these 2 classes may produce additive CV benefits. The SGLT2i and GLP-1 RAs also reduced macroalbuminuria, decreased the time for doubling of serum creatinine, and slowed the time to end-stage renal disease. In this perspective, we review the potential benefit of combination SGLT2i/GLP-1 RA therapy on metabolic-cardiovascular-renal disease in patients with type 2 diabetes mellitus.

Idioma originalEnglish (US)
Páginas (desde-hasta)1353-1362
Número de páginas10
PublicaciónDiabetes, Obesity and Metabolism
EstadoPublished - oct 2017

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Profundice en los temas de investigación de 'Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor'. En conjunto forman una huella única.

Citar esto